Department of Basic Medical Sciences, Neurosciences and Sensory Organs, Section of Human Anatomy and Histology, University of Bari Medical School, Bari, Italy.
Neoplasia. 2013 Mar;15(3):231-8. doi: 10.1593/neo.121962.
The role of angiogenesis in the growth of lymphomas and survival of patients with leukemias and other hematological malignancies has become evident since 1994. Angiogenic factors, such as vascular endothelial growth factor and its receptors together with other tumor microenvironment components, including myelo-monocytic cell, mast cells, endothelial progenitor cells, and circulating endothelial cells, have been shown to be important in the progression and maintenance of lymphoproliferative disorders. In this review article, we present an overview of the literature focusing on the relationship between angiogenesis and disease progression and the recent advantages in the antiangiogenic treatment in human non-Hodgkin lymphomas.
自 1994 年以来，血管生成在淋巴瘤的生长以及白血病和其他血液系统恶性肿瘤患者的生存中的作用已经变得很明显。血管生成因子，如血管内皮生长因子及其受体，以及其他肿瘤微环境成分，包括髓系单核细胞、肥大细胞、内皮祖细胞和循环内皮细胞，已被证明在淋巴增生性疾病的进展和维持中很重要。在这篇综述文章中，我们概述了文献，重点关注血管生成与疾病进展之间的关系，以及在人类非霍奇金淋巴瘤的抗血管生成治疗方面的最新进展。
